Regulators said they have told Mylan that it should be paying higher rebates on sales of EpiPens through Medicaid. » Read More
US Senators asked the Justice Department to investigate if Mylan misclassified its EpiPen to pay lower rebates to the states. » Read More
A restatement by Mylan of EpiPen profit figures is just the latest problem for the drugmaker.
The cost of naloxone has spiraled upwards, even as the drug has become more desperately needed to reverse overdoses.
If implemented, Clinton's plan would increase the number of Americans insured while Trump's would not.
The nation's uninsured rate would spike under Trump's health plan, but fall further under Clinton's, a study finds.
The days of company pensions are long gone for most workers; that is why investing in an annuity can be an appealing strategy for retirees.
John Nelson, Lloyd's of London chairman, discusses the specialist insurance company's latest results and says market conditions are challenging.
Mylan also faces heat from multiple regulatory and legal agencies over huge cost increases for the anti-allergy auto-injectors.
Start-ups, such as Lemonade and Teambrella, are using peer-to-peer strategies to disrupt to the trillion-dollar insurance industry.
Mylan CEO Heather Bresch is set to testify Wednesday before a House committee over sky-high price hikes for lifesaving EpiPens.
Senate Finance Committee on Tuesday said it asked the Department of Health to investigate the rebates to state Medicaid programs for Mylan's EpiPen treatment.
Less than 10 percent of authorized doctors prescribe the medication buprenorphine to more than 75 patients.
ICICI Bank CEO Chanda Kochhar says the listing of ICICI Prudential life Insurance is huge leap forward for India's capital markets and financial sector.
Despite rising Obamacare prices, the total premiums paid in many cases are less than work-based coverage.
Drugmakers need to learn empathy and not try to defend price hikes that make drugs inaccessible, GSK CEO Andrew Witty told CNBC.
CNBC's David Faber reports the latest on the merger between Anthem and Cigna.
Lloyd's of London Chairman John Nelson explains that the insurer remains competitive because of its specialties and relevant new products.
Get the best of CNBC in your inbox